



Significant opportunities exist to improve the Safety, Efficacy and Patient Compliance of many drugs approved by the FDA in the 60's, 70's and 80's, using new technologies and achieve regulatory approval expeditiously.

CONTACT INFORMATION

Prabu Nambiar, PhD, MBA, RAC, President & CEO

Email: prabu.nambiar@pranabiosciences.com

Phone: 774.288.9842

About PraNa Biosciences, Inc.

- ❖ Established in 2015
- ❖ Delaware Inc.,
- ❖ Headquarters and R&D located in Massachusetts
- ❖ Development of improved formulations of approved drugs
- ❖ Development of complex generics by applying innovative technologies
- ❖ 4 compounds under development in CNS and Pain Management

Drug Candidate Selection Strategy

- ❖ Complex Dosage-forms
- ❖ Modified release, Inhalation products, New routes of delivery
- ❖ US market annual sales of \$200MM or higher
- ❖ Technology can be protected by Patents
- ❖ Faster route to Regulatory approval - preferably 505(b)(2) pathway
- ❖ Expedited development and lower clinical development cost

MANAGEMENT TEAM

- ❖ *Prabu Nambiar, PhD, MBA*
President & CEO, 25+ Years of pharma experience
- ❖ *Gary Maier, PhD*
VP Clinical Affairs, 25+ Years of pharma experience
- ❖ *Gee Easo, BS*
VP R&D Operations, 20+ Years of pharma experience

- ❖ *Binesh Prabhakar, MS, MBA*
VP Corporate Development, 15+ Years of pharma experience
- ❖ *William O'Brien, Esq., LLM*
VP Legal Affairs, Leadership roles at start-up firms
- ❖ *Dr. Sanjoy Banerjee, MD, QME*
Chief Medical Advisor, Board Certified, in Anesthesiology, Pain Medicine and Addiction Medicine

CURRENT PIPELINE

PRA-10001 - Improved formulation of metaxalone for musculoskeletal pain

- ❖ *Improved Formulation* – Lower Dosage | Quicker Action
- ❖ *Clinical Benefits* – Improved Safety | Less side effects
- ❖ *505(b)(2) NDA* – Quicker Regulatory Path; Lower development cost, Pre-IND consult with FDA completed
- ❖ *Intellectual Property* – Clinical Exclusivity and Patent protection

PRA-1012 - COX-2 inhibitor, improved formulation

- ❖ *Improved Formulation* – Lower Dosage | **Potential to remove or minimize black box warning (GI irritation and cardiac side effects)**
- ❖ *Clinical Benefits* – Improved Safety | Less side effects
- ❖ *505(b)(2) NDA* – Quicker Regulatory Path; Lower development cost
- ❖ *Intellectual Property* – Clinical Exclusivity and Patent protection

WE ARE LOOKING FOR

A Development Partner

- ❖ Co-develop the product
- ❖ Approval through 505(b)(2) pathway
- ❖ Commercial and Marketing

An Out Licensing Partner

- ❖ License the product to the partner
- ❖ Technology transfer
- ❖ Approval through 505(b)(2) pathway